News about "pharmacokinetics "

Ascletis Initiates US Phase 1 Study of Oral ASC36 for Obesity

Ascletis has initiated a US Phase 1 study of ASC36, an investigational oral amylin receptor peptide agonist developed using the company’s proprietary oral peptide delivery technology.

Pharmacokinetics | 09/09/2026 | By News Bureau

Rezubio Advances RZ-520 Into Phase 1 Trial Following FDA and NMPA Clearances

Rezubio has dosed the first cohort in a Phase 1 trial evaluating RZ-520, an investigational inhaled therapy for chronic respiratory diseases.

Pharmacokinetics | 08/09/2026 | By News Bureau

Entod Pharmaceuticals Launches Project AXIOM to Explore Novel Myopia Therapy

Entod Pharmaceuticals has launched Project AXIOM, an India-led research programme exploring retinal dopaminergic modulation as a potential approach to slowing progressive myopia.

Pharmacokinetics | 27/08/2026 | By News Bureau

Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013

Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.

Pharmacokinetics | 27/07/2026 | By News Bureau |  188

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Trial of AT-587 for Hepatitis E Treatment

Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial evaluating AT-587, an investigational oral antiviral candidate for hepatitis E virus (HEV) infection. The study will assess the drug's safety and pharmacokinetics, supporting the development of a potential new treatment for chronic HEV, particularly in immunocompromised patients.

Pharmacokinetics | 17/07/2026 | By News Bureau |  150

IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours

IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.

Pharmacokinetics | 11/03/2026 | By News Bureau |  337

IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC

Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.

Pharmacokinetics | 02/03/2026 | By News Bureau |  305

Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme

Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.

Pharmacokinetics | 20/01/2026 | By News Bureau |  538

D3 Bio Secures FDA IND Clearances to Advance KRAS G12D and KRAS G12C Oncology Programmes into Clinical Trials

D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.

Pharmacokinetics | 19/01/2026 | By News Bureau |  850

Just-Evotec Biologics Secures Gates Foundation Grant to Expand Global Access to Biotherapeutics

The funding will support ten new molecular design projects over three years, leveraging Just-Evotec Biologics’ J.MD computational platform to optimise monoclonal antibodies and other biologics, reduce development costs and improve access to affordable therapies for infectious diseases in low- and middle-income countries.

Pharmacokinetics | 12/01/2026 | By News Bureau |  261